2024-11-17 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison and Deviation:**

Merck & Co Inc (MRK) is a leading pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of innovative medicines and vaccines.

Over the analyzed period, MRK's cumulative return (63.29%) significantly underperformed the S&P 500 (VOO) index's cumulative return (123.86%).  The difference is a substantial -60.57%.  This places MRK's relative performance at the 6.38th percentile of its historical range (max: 47.45%, min: -67.93%), indicating a relatively poor performance compared to the S&P 500.

The provided Alpha and Beta analysis shows varying performance relative to the market (Beta < 1 indicates lower volatility than the market) over different timeframes.  Alpha, while generally positive, fluctuates suggesting periods of outperformance and underperformance relative to market benchmarks.

**2. Recent Price Movement:**

* **Closing Price:** $96.31
* **5-Day Moving Average:** $98.50
* **20-Day Moving Average:** $102.35
* **60-Day Moving Average:** $110.03

The current price is below all three moving averages, suggesting a downward trend in the short to medium term.  This confirms the negative 20-day relative divergence (-18.32%).


**3. Technical Indicators and Expected Return:**

* **RSI (22.69):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.31):**  Shows a negative momentum, confirming the downward trend.
* **20-Day Relative Divergence (-18.32):** Shows a significant short-term downward trend.
* **Expected Return (0.0%):**  The provided 0% expected return over the long term (2+ years) relative to the S&P 500 requires further clarification and analysis.  It's crucial to understand the basis of this estimate.  Given the historical underperformance against the S&P 500, a 0% return suggests the analyst is not expecting outperformance, at best. The significant divergence between the price and moving averages could indicate a correction could lead to a temporary increase in value, however, this would not be a reliable forecast for long-term performance.

**4. Recent Financial Performance:**

The provided earnings data shows some fluctuation in EPS and revenue.  While the latest reported EPS ($1.25) is lower than the previous quarter's EPS ($2.15), it's important to have context, such as the projected EPS and any significant factors that influenced the drop.  Consistent revenue growth is evident; however further investigation is needed to determine the long-term trajectory.  Providing details on the anticipated EPS would improve the analysis.

**5. Financial Information Analysis:**

The financial data reveals high profit margins consistently above 70%.  However, Return on Equity (ROE) shows significant volatility, highlighting potential risks and uncertainties in profitability. The negative ROE in Q4 2023 is a cause for concern and requires further investigation.

**6. News and Recent Issues:**

*(This section requires information from recent news sources like Shacknews and Finbold.  Please provide specific news articles for a complete analysis.  Without this information, I cannot provide commentary on recent market outlook, analyst opinions, or performance highlights.)*


**7. Summary of Analysis:**

MRK's recent performance has significantly lagged the S&P 500.  While technical indicators suggest the stock may be oversold, the negative momentum and consistent underperformance raise concerns.  The high profit margins and generally consistent revenue growth are positive factors.  However, volatile ROE and the recent decline in EPS warrant further investigation.  Comprehensive analysis requires up-to-date news regarding earnings, analyst opinions, and market outlook. The projected long-term returns should also be investigated for reliability.

**8. Conclusion:**

Based on the provided data, MRK presents a mixed picture.  While possessing a strong business model and exhibiting consistent revenue, the recent performance against market benchmarks and volatility in key financial metrics raise questions about long-term investment prospects.  Additional information on recent news, analyst sentiment, and a detailed explanation of the expected return is needed for a more conclusive assessment.  Further investigation into the reasons behind the fluctuating EPS and ROE, along with the comparison to industry peers, is recommended before making any investment decisions.
